Portfolio

The ELIOS™ procedure offers an implant-free, minimally invasive glaucoma surgery (MIGS) option that creates precise microscopic channels inside the eye that may increase the flow of fluid and lower eye pressure.

Publication:

Current review of Excimer laser Trabeculostomy

Developing next generation long acting biodegradable drug delivery  platform.

News:

Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing

Dr. Rahhal Interview Re-Vana Therapeutics, Ltd. CEO Michael O'Rourke

Revolutionizing microsurgery through advancements in robotics, medical imaging, and artificial intelligence.

News:

Dr. Hubschman, Founder and CEO presents at OIS

Follow on LinkedIn

Enabling delivery of precision RNA therapeutics

News:

Completes $100M Series B to Advance its FALCON™ Platform and RNA Therapeutics

Publication:

Biocentury | DTx: Optimizing RNA therapies for cellular uptake, biodistribution

Developing novel compounds to treat corneal dystrophies

News:

Restoring vision loss with a regenerative therapy

Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial

Publications:

Proliferation of Human Corneal Endothelia in Organ Culture Stimulated by Wounding and the Engineered Human Fibroblast Growth Factor 1 Derivative TTHX1114

A Bell-Shaped Dose Response of Topical FGF-1 in Dermal Wound Healing

Implantable intraocular pressure sensor

News:

Qura receives strategic investment from Santen Ventures

Revolutionizing the eye exam

News:

Envision Diagnostics raises Series A Financing

Publication:

Automated Pupillometry Using a Prototype Binocular OCT System

Quantum Dots to treat retinal disease 

Studies:

Library

Pioneering an entirely new approach to preserving sight

News:

ONL Therapeutics Closes $46.9 Million in Series B

ONL Therapeutics featured on the OIS Retina Podcast with Dr. Rahhal

ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204

(Acquired: Allergan) 
First-in-class optogenetic therapy to treat retinal diseases 

News:
Allergan Acquires Gene Therapy Company RetroSense Therapeutics